WASHINGTON — All U.S. women getting mammograms will soon receive information about their breast density, which can sometimes make cancer harder to spot.
The new requirements, finalized Thursday by the Food and Drug Administration, are aimed at standardizing the information given to millions of women following scans to detect breast cancer. Regulators first proposed the changes in 2019 and health care providers will have 18 months to comply with the policy.
Some states already require that women receive information on breast density.
Alpilean has been receiving a lot of hype lately for being one of the most popular and safe weight loss supplements this year. It is formulated with a proprietary blend of six potent Alpine ingredients that work to reduce weight distinctively.
The manufacturers of Alpilean supplement formulated this revolutionary product with the help of recent research that discovered a common factor in most obese men and women – low inner body temperature. Alpilean weight loss formula follows this research to increase and regulate the inner body temperature which ensures a fast and effortless calorie burn.
This weight loss supplement comes in the form of capsules which makes it safe and easy to use.
About half of women over age 40 have dense breasts, with less fatty tissue and more connective and glandular tissue. That tissue appears white on X-rays, the same color as growths in the breast, making mammograms harder to read. Dense breast tissue is one of the factors that can increase a woman’s chances of developing cancer.
Under the new rules, women with dense breasts will receive a written memo alerting them that their status “makes it harder to find breast cancer.” Those patients will also be directed to speak with their doctor about their results.
Professional guidelines don’t specify next steps for women identified with dense breasts, but some physicians may recommend additional forms of scanning, including ultrasound or MRI.
